Elise Chiffoleau
  • E-mail :[email]
  • Phone : +33 2 44 76 81 89
  • Location : Nantes, France
Last update 2018-06-29 13:08:59.242

Elise Chiffoleau CR1 INSERM

Course and current status

E. Chiffoleau completed her Ph.D. degree (1999-2002) in UMR Nantes-INSERM on the identification and characterization of new molecules involved in allograft tolerance. She performed a postdoctoral position (2002-2003) at the University of Pennsylvania, Philadelphia, in the laboratory of Dr. Laurence Turka. Her research was on the study of the mechanisms and molecular pathways of molecules (TRAF6, BclXL, Notch) involved in allograft or self-tolerance. She then obtained a permanent position at the UMR 1064 (University of Nantes, Inserm, CNRS). E. Chiffoleau belogs to team 1 of UMR1064 Center for Research in Transplantation and Immunology (CRTI) (http://crti.univ-nantes.fr/) that is a joint research unit created by INSERM and Université de Nantes in 2012 and renewed in 2017. CRTI is historically the evolution of previous units devoted to transplant immunology for almost 20 years in Nantes and constitutes with several clinical departments the Institute of Transplantation Urology and Nephrology (ITUN), one of the largest French and European kidney transplantation centers. CRTI gathers researchers and clinicians with expertise in basic immunology, transplantation, autoimmunity, inflammation, virology, nephrology, regenerative medicine, genetic and bioinformatics and who develop innovative projects going from basic to clinical research. Her team is interested in understanding the cellular and molecular mechanisms of immunoregulation in the context of organ transplantation, immune-mediated inflammatory diseases (IMIDs) and immune response to persistent virus. They aim to identify new immunoregulatory cellular and molecular targets and to translate these findings for clinical application as innovative therapeutics or biomarkers.

Scientific summary

We previously identified CLEC-1, as being over-expressed in experimental model of allograft tolerance. CLEC-1 belongs to the "C-type lectin receptor" (CLR) family expressed mostly by myeloid cells and that recognize molecular patterns expressed by exogenous and endogenous threats, but also various proteins and lipids (e.g. DECTIN-1). Besides, CLR act as inhibitory or activating receptors to modulate myeloid cell activation, as well as magnitude and quality of downstream T cell response. We previously published that CLEC-1 is expressed in rat by immature myeloid cells and moderates the subsequent Th17 CD4+ T cell response (Thebault et al. J of Immunol 2009). The generation of rat CLEC-1 Fc fusion protein and CLEC-1 knockout rats (in collaboration with the TRIP platform, I Anegon) confirmed its role in DCs in the inhibition of effector Th1 and Th17 responses (Lopez-Robles Blood Adv. 2017). Furthermore, we demonstrated the expression of CLEC-1 on human dendritic cells and its role in the inhibition of subsequent Th responses . Therefore, the patent PCT/EP2017/076911 entitled "Patent Methods & pharmaceutical compositions for promoting T cell responses, has been deposit in July 2017. Funding: IHU-CESTI (2013-2016), Agence de la Biomédecine (2015-2016), Ligue (2017), Labex IGO 2018.

Image d’exemple